Methods and compositions for immunizing against chlamydia infection
AssigneesTrinity Biosystems, Inc., Children's Hospital & Research Center at Oakland
InventorsRandall J. Mrsny, Deborah Dean
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to methods and compositions for immunizing against infection by Chlamydia trachomatis. The methods and compositions rely, in part, on administering an immunogenic composition comprising one or more peptides derived from C. trachomatis major outer membrane protein (MOMP) to a subject to be immunized. In some embodiments, the compositions comprise a chimeric immunogen comprising a receptor binding domain, a translocation domain, and a Chlamydia trachomatis antigen. Polynucleotides encoding the chimeric immunogens, expression vectors comprising the polynucleotides, and kits comprising the compositions are also provided.
Claims62
A chimeric immunogen, comprising
- a)—a receptor binding domain,
- b)—a translocation domain, and
- c)—a Chlamydia trachomatis antigen comprising an amino acid sequence according to Formula I:
- Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20-Xaa21-Xaa22-Xaa23-Xaa24-Xaa25-Xaa26-Xaa27, Formula I
- wherein Xaa1 is A, V, or absent;
- Xaa2 is E, T, K, or absent;
- Xaa3 is A, T, P, or absent;
- Xaa4 is I, V, or absent;
- Xaa5 is F, L, V, or absent;
- Xaa6 is D or absent;
- Xaa7 is V, T, I, or absent;
- Xaa8 is T;
- Xaa9 is T;
- Xaa10 is L;
- Xaa11 is N;
- Xaa12 is P or R;
- Xaa13 is T;
- Xaa14 is T or I;
- Xaa15 is A or T;
- Xaa16 is G;
- Xaa17 is A, C, K, or absent;
- Xaa18 is G or absent;
- Xaa19 is S, G, T, A, E, D, or absent;
- Xaa20 is V or absent;
- Xaa21 is A, V, I, K, or absent;
- Xaa22 is A, G, S, T, or absent;
- Xaa23 is A, G, N, S, or absent;
- Xaa24 is G, N, or absent;
- Xaa25 is A, S, T, or absent;
- Xaa26 is D, E, or absent;
- and Xaa27 is G, N, or absent (SEQ ID NO.:42).
A chimeric immunogen, comprising
- a)—a receptor binding domain,
- b)—a translocation domain, and
- c)—a Chlamydia trachomatis antigen comprising an amino acid sequence according to Formula II:
- Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6, Formula II
- wherein Xaa1 is A, S;
- Xaa2 is G;
- Xaa3 is T;
- Xaa4 is D or E, Xaa5 is A or G;
- and Xaa6 is A or V (SEQ ID NO.:2).
A chimeric immunogen, comprising
- a)—a receptor binding domain,
- b)—a translocation domain, and
- c)—a Chlamydia trachomatis antigen comprising an amino acid sequence according to Formula III:
- Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20-Xaa21-Xaa22-Xaa23, Formula III
- wherein Xaa1 is G;
- Xaa2 is A, D, or E;
- Xaa3 is A, E, or K;
- Xaa4 is L or P;
- Xaa5 is A or T;
- Xaa6 is A, G, S, T, or V;
- Xaa7 is K, N, R, S, or absent;
- Xaa8 is A, D, or absent;
- Xaa9 is A, D, I, S, T, or V;
- Xaa10 is A, E, G, T, or V;
- Xaa11 is D, G, or N;
- Xaa12 is L, N, or T;
- Xaa13 is A, E, Q, S, or T;
- Xaa14 is A, K, N, S, or T;
- Xaa15 is A, D, or T;
- Xaa16 is L or P;
- Xaa17 is K, S, T, or V;
- Xaa18 is I, K, T, or V;
- Xaa19 is C, L, or N;
- Xaa20 is I, T or V;
- Xaa21 is A or E;
- Xaa22 is R;
- and Xaa23 is E, P, or T (SEQ ID NO.:3).
A chimeric immunogen, comprising
- a)—a receptor binding domain,
- b)—a translocation domain, and
- c)—a Chlamydia trachomatis antigen comprising an amino acid sequence according to Formula IV:
- Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-Xaa19-Xaa20-Xaa21-Xaa22-Xaa23-Xaa24-Xaa25-Xaa26-Xaa27, Formula IV
- wherein Xaa1 is A or V;
- Xaa2 is E, T, or K;
- Xaa3 is A, T, or P;
- Xaa4 is I or V;
- Xaa5 is F, L, or V;
- Xaa6 is D;
- Xaa7 is V, T, or I;
- Xaa8 is T;
- Xaa9 is T;
- Xaa10 is L;
- Xaa11 is N;
- Xaa12 is P or R;
- Xaa13 is T;
- Xaa14 is T or I;
- Xaa15 is A or T;
- Xaa16 is G;
- Xaa17 is A, C, or K;
- Xaa18 is G;
- Xaa19 is S, G, T, A, E, or D;
- Xaa20 is V;
- Xaa21 is A, V, I, or K;
- Xaa22 is A, G, S, or T;
- Xaa23 is A, G, N, or S;
- Xaa24 is G, N, or absent;
- Xaa25 is A, S, or T;
- Xaa26 is D or E;
- and Xaa27 is G or N (SEQ ID NO.:1).
A chimeric immunogen, comprising
- a)—a receptor binding domain,
- b)—a translocation domain, and
- c)—a Chlamydia trachomatis antigen comprising an amino acid sequence that is selected from the group consisting of AGTEAA (SEQ ID NO.:4), AGTDAA (SEQ ID NO.:5), AETIFDVTTLNPTIAGAGDVKTSAEG (SEQ ID NO.:6), AETILDVTTLNPTIAGKGTVVTSAE (SEQ ID NO.:7), TTLNPTIAGC (SEQ ID NO.:8), GAKPTATTGNATAPSTLTARE (SEQ ID NO.:9), TTSDVAGLQNDPC (SEQ ID NO.:10), SEFTINKPKGYVGKE (SEQ ID NO.:
- 11), ILWEGFGGDPCDPCTT (SEQ ID NO.:12), ALNIWDRFDV (SEQ ID NO.:13), KMKSRKSCGIAVGTTVVSADKYAVT (SEQ ID NO.:14), CAETIFDVTTLNPTIAGAGDVKTSAEGC (SEQ ID NO.:15), CAETILDVTTLNPTIAGKGTVVTSAEC (SEQ ID NO.:16), CTTLNPTIAGC (SEQ ID NO.:17), CGAKPTATTGNATAPSTLTAREC (SEQ ID NO.:18), and CTTSDVAGLQNDPC (SEQ ID NO.:19),
- wherein said chimeric immunogen, when administered to a subject, induces an immune response in said subject that is effective to reduce adherence of a microorganism that expresses said C. trachomatis antigen to epithelial cells of said subject.
-43. (canceled)
A polynucleotide that encodes a chimeric immunogen, said chimeric immunogen comprising:
- a)—a receptor binding domain,
- b)—a translocation domain, and
- c)—a C. trachomatis antigen comprising an amino acid sequence that is selected from the group consisting of AGTEAA (SEQ ID NO.:4), AGTDAA (SEQ ID NO.:5), AETIFDVTTLNPTIAGAGDVKTSAEG (SEQ ID NO.:6), AETILDVTTLNPTIAGKGTVVTSAE (SEQ ID NO.:7), TTLNPTIAGC (SEQ ID NO.:8), GAKPTATTGNATAPSTLTARE (SEQ ID NO.:9), TTSDVAGLQNDPC (SEQ ID NO.:10), SEFTINKPKGYVGKE (SEQ ID NO.:
- 11), ILWEGFGGDPCDPCTT (SEQ ID NO.:12), ALNIWDRFDV (SEQ ID NO.:
- 13), KMKSRKSCGIAVGTTVVSADKYAVT (SEQ ID NO.:14), CAETIFDVTTLNPTIAGAGDVKTSAEGC (SEQ ID NO.:15), CAETILDVTTLNPTIAGKGTVVTSAEC (SEQ ID NO.:16), CTTLNPTIAGC (SEQ ID NO.:17), CGAKPTATTGNATAPSTLTAREC (SEQ ID NO.:18), and CTTSDVAGLQNDPC (SEQ ID NO.:19),
- wherein said chimeric immunogen, when administered to a subject, induces an immune response in said subject that is effective to reduce adherence of a microorganism that expresses said C. trachomatis antigen to epithelial cells of said subject.
-90. (canceled)
-97. (canceled)
A method for generating in a subject antibodies specific for a Chlamydia trachomatis peptide comprising an amino acid sequence that is selected from the group consisting of AGTEAA (SEQ ID NO.:4), AGTDAA (SEQ ID NO.:5), AETIFDVTTLNPTIAGAGDVKTSAEG (SEQ ID NO.:6), AETILDVTTLNPTIAGKGTVVTSAE (SEQ ID NO.:7), TTLNPTIAGC (SEQ ID NO.:8), GAKPTATTGNATAPSTLTARE (SEQ ID NO.:9), TTSDVAGLQNDPC (SEQ ID NO.:10), SEFTINKPKGYVGKE (SEQ ID NO.:11), ILWEGFGGDPCDPCTT (SEQ ID NO.:12), ALNIWDRFDV (SEQ ID NO.:13), KMKSRKSCGIAVGTTVVSADKYAVT (SEQ ID NO.:14), CAETIFDVTTLNPTIAGAGDVKTSAEGC (SEQ ID NO.:15), CAETILDVTTLNPTIAGKGTVVTSAEC (SEQ ID NO.:16), CTTLNPTIAGC (SEQ ID NO.:
- 17), CGAKPTATTGNATAPSTLTAREC (SEQ ID NO.:18), and CTTSDVAGLQNDPC (SEQ ID NO.:19), comprising administering to said subject an immunogenic amount of a chimeric immunogen comprising a receptor binding domain, a translocation domain, and a Chlamydia trachomatis peptide comprising an amino acid sequence that is selected from the group consisting of AGTEAA (SEQ ID NO.:4), AGTDAA (SEQ ID NO.:5), AETIFDVTTLNPTIAGAGDVKTSAEG (SEQ ID NO.:6), AETILDVTTLNPTIAGKGTVVTSAE (SEQ ID NO.:7), TTLNPTIAGC (SEQ ID NO.:8), GAKPTATTGNATAPSTLTARE (SEQ ID NO.:9), TTSDVAGLQNDPC (SEQ ID NO.:10), SEFTINKPKGYVGKE (SEQ ID NO.:11), ILWEGFGGDPCDPCTT (SEQ ID NO.:12), ALNIWDRFDV (SEQ ID NO.:13), KMKSRKSCGIAVGTTVVSADKYAVT (SEQ ID NO.:14), CAETIFDVTTLNPTIAGAGDVKTSAEGC (SEQ ID NO.:15), CAETILDVTTLNPTIAGKGTVVTSAEC (SEQ ID NO.:16), CTTLNPTIAGC (SEQ ID NO.:
- 17), CGAKPTATTGNATAPSTLTAREC (SEQ ID NO.:18), and CTTSDVAGLQNDPC (SEQ ID NO.:19), thereby generating antibodies specific for said C. trachomatis peptide.
-106. (canceled)
A C. trachomatis antigen having an amino acid sequence that is selected from the group consisting of AETIFDVTTLNPTIAGAGDVKTSAEG (SEQ ID NO.:6), AETILDVTTLNPTIAGKGTVVTSAEC (SEQ ID NO.:7), TTLNPTIAGC (SEQ ID NO.:8), GAKPTATTGNATAPSTLTARE (SEQ ID NO.:9), TTSDVAGLQNDPC (SEQ ID NO.:10), SEFTINKPKGYVGKE (SEQ ID NO.:11), ILWEGFGGDPCDPCTT (SEQ ID NO.:12), ALNIWDRFDV (SEQ ID NO.:13), KMKSRKSCGIAVGTTVVSADKYAVT (SEQ ID NO.:14), CAETIFDVTTLNPTIAGAGDVKTSAEGC (SEQ ID NO.:15), CAETILDVTTLNPTIAGKGTVVTSAEC (SEQ ID NO.:16), CTTLNPTIAGC (SEQ ID NO.:
- 17), CGAKPTATTGNATAPSTLTAREC (SEQ ID NO.:18), and CTTSDVAGLQNDPC (SEQ ID NO.:19).
-128. (canceled)
-136. (canceled)
Dependencies are inferred from the claim text.